Mouse anti p53 do 1 sc 126

Stress inducers and inhibitors: PD173074, staurosporine, anisomycin, etoposide, brefeldin A, thapsigargin, doxorubicin and Fas ligand were from Sigma-Aldrich (MO, USA). Actinomycin D and camptothecin were from Santa Cruz Biotechnology (TX, USA). ABT 737, BTSA-1, BGJ398, ARQ087 were from Selleckchem (TX, USA), Apo2/TRAIL was from Merck (Darmstadt, Germany). The following primary antibodies were used: rabbit anti-PARP1/2 (9542), rabbit anti-BAX (D2E11) (5023), rabbit anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (9101) from Cell Signaling Technology (MA, USA), mouse anti-gamma tubulin (T6557) from Sigma-Aldrich, goat anti-FGF1 (sc-1884), mouse His-tag (H3) (sc-8036) and mouse anti-p53 DO-1 (sc-126) from Santa Cruz Biotechnology. Rabbit polyclonal antibodies against FGF1 (OPA1) were generated by Davids Biotechnologie GmbH (Regensburg, Germany) by immunizing rabbits with purified FGF1. The following HRP-conjugated secondary antibodies from Jackson Immuno Research Laboratories (PA, USA) were used: peroxidase affinipure goat anti-rabbit IgG (111-035-144) and anti-mouse IgG (115-035-003).

The following antibodies were used: mouse anti-p53 (DO-1, sc-126) from Santa Cruz Biotechnology; rabbit anti-FOXQ1 (PA5-40772) and rabbit anti-Histone H3 (PA5-16183) from Invitrogen; mouse anti-FLAG M2 (F3165) from Sigma–Aldrich; rabbit anti-HSP70 (AF1663) from R&D Systems; and IRDye 800CW Streptavidin from LI-COR. Nutlin-3 and doxorubicin were purchased from Sigma–Aldrich. siRNAs were obtained from Integrated DNA Technologies.